Medicamen Biotech Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹669.5
- Today's High:
- ₹705
- Open Price:
- ₹701
- 52W Low:
- ₹602.05
- 52W High:
- ₹1217.8425
- Prev. Close:
- ₹699.7
- Volume:
- 5121
Company Statistics
- Market Cap.:
- ₹4.81 billion
- Book Value:
- 99.664
- Revenue TTM:
- ₹1.22 billion
- Operating Margin TTM:
- 12.74%
- Gross Profit TTM:
- ₹450.64 million
- Profit Margin:
- 10.03%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Medicamen Biotech Limited had its IPO on under the ticker symbol 531146.
The company operates in the Healthcare sector and Drugs - Generic industry. Medicamen Biotech Limited has a staff strength of 264 employees.
Stock update
Shares of Medicamen Biotech Limited opened at ₹701 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹669.5 - ₹705, and closed at ₹678.45.
This is a -3.04% slip from the previous day's closing price.
A total volume of 5,121 shares were traded at the close of the day’s session.
In the last one week, shares of Medicamen Biotech Limited have slipped by -5.54%.
Medicamen Biotech Limited's Key Ratios
Medicamen Biotech Limited has a market cap of ₹4.81 billion, indicating a price to book ratio of 3.7885 and a price to sales ratio of 3.7588.
In the last 12-months Medicamen Biotech Limited’s revenue was ₹1.22 billion with a gross profit of ₹450.64 million and an EBITDA of ₹178.72 million. The EBITDA ratio measures Medicamen Biotech Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Medicamen Biotech Limited’s operating margin was 12.74% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Medicamen Biotech Limited’s quarterly earnings growth was a negative -33.1% while revenue growth was a negative 10.7%.
Medicamen Biotech Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 37.4776
- PEG
Its diluted EPS in the last 12-months stands at ₹10.032 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Medicamen Biotech Limited’s profitability.
Medicamen Biotech Limited stock is trading at a EV to sales ratio of 3.8392 and a EV to EBITDA ratio of 23.2553. Its price to sales ratio in the trailing 12-months stood at 3.7588.
Medicamen Biotech Limited stock pays annual dividends of ₹0.5 per share, indicating a yield of 0.13% and a payout ratio of 7.17%.
Balance sheet and cash flow metrics
- Total Assets
- ₹2.79 billion
- Total Liabilities
- ₹825.74 million
- Operating Cash Flow
- ₹-58804000.00
- Capital Expenditure
- ₹66.01 million
- Dividend Payout Ratio
- 7.17%
Medicamen Biotech Limited ended 2024 with ₹2.79 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹2.79 billion while shareholder equity stood at ₹1.93 billion.
Medicamen Biotech Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹825.74 million in other current liabilities, 126511000.00 in common stock, ₹1.81 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹207.79 million and cash and short-term investments were ₹207.79 million. The company’s total short-term debt was ₹233,131,000 while long-term debt stood at ₹0.
Medicamen Biotech Limited’s total current assets stands at ₹1.63 billion while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹652.58 million compared to accounts payable of ₹0 and inventory worth ₹450.57 million.
In 2024, Medicamen Biotech Limited's operating cash flow was ₹-58804000.00 while its capital expenditure stood at ₹66.01 million.
Comparatively, Medicamen Biotech Limited paid ₹0.07 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹678.45
- 52-Week High
- ₹1217.8425
- 52-Week Low
- ₹602.05
- Analyst Target Price
- ₹
Medicamen Biotech Limited stock is currently trading at ₹678.45 per share. It touched a 52-week high of ₹1217.8425 and a 52-week low of ₹1217.8425. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹752.14 and 200-day moving average was ₹735.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6449.1% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Medicamen Biotech Limited
Similar Industry Stocks (Drugs - Generic)
Most Active
Top Gainers
Top Losers
About
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, ointments, and oral rehydration solutions. It also provides oral rehydration solution, mouth wash, and dental care products. The company was founded in 1993 and is headquartered in New Delhi, India.